#1 - Agenus (NASDAQ:AGEN)
Our first stock is in the biotechnology sector. Agenus Inc. (NASDAQ: AGEN) is a clinical-stage biotechnology company. The company's mission is to "harness the power of the immune system to bring curative therapies to cancer patients." This focus on immuno-oncology ties directly to the enhanced focus on cancer research.
Agenus has a robust pipeline, but nothing is commercially available at this time. However, the company is forecasting a Biologics License Application (BLA) for its lead candidate for Metastatic MSS Colorectal Cancer in mid-2024. This is an important step, but it's only the beginning of the process.
That means investors should be playing the long game with AGEN stock. But if they have the risk tolerance, analysts are lining up behind the stock. The Agenus analyst ratings on MarketBeat give the stock a consensus Buy rating with a price target of $7.10, which would make the stock more than a 10-bagger from its March 26, 2024, price of 55 cents.
About Agenus
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Read More - Current Price
- $11.47
- Consensus Rating
- Buy
- Ratings Breakdown
- 3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $70.00 (510.3% Upside)
